. Author manuscript; available in PMC: 2008 Mar 1.

Published in final edited form as: Mol Immunol. 2006 Dec 14;44(9):2228–2234. doi: 10.1016/j.molimm.2006.11.012

Table 1.

Complement activation on human endothelial cells.

Cells/Conditions	Antibody Binding (Ratio Relative to Control)
	Anti C1q	Anti C4d/C4	Anti iC3b	Anti scC5b-9
BMEC/Plasma	1	1	1	1
HUVEC/Plasma (n=3)	0.80 ± 0.16	0.90 ± 0.28	0.92 ± 0.22	0.84 ± 0.32
Brain micro-vascular EC/Plasma (n=3)	1.18 ± 0.20	0.89 ± 0.36	1.27 ± 0.20	0.85 ± 0.19
BMEC/74.5.2 F(ab’)₂ Plasma (n=6)	NA	0.77 ± 0.15^*	NA	NA
BMEC/C1q depleted Serum (n=3)	0.012 ± 0.03^*	0.006 ± 0.04^*	0.238 ± 0.12^*	−0.016 ± 0.20^*
BMEC/Factor B depleted Serum (n=3)	0.93 ± 0.24	0.83 ± 0.17	1.01 ± 0.19	0.79 ± 0.33
BMEC/NHS (n=4)	1.35 ± 0.65	1.36 ± 0.56	0.88 ± 0.09	0.76 ± 0.29

Complement activation on cultured endothelial cells derived from different vascular beds was investigated using plasma or serum to assess the involvement of classical pathway (C1q-deficient plasma), alternative pathway (Factor B depleted serum) and gC1qR (74.5.2). The data are expressed as mean ± S.D., reflecting changes in antigen expression relative to resting BMEC (control).

denotes statistical significance p<0.05

NA – study not performed.